Importance: Recent years, breast cancer (BC) was the most common cancer that occupied the first place, among the primary patients with malignant tumors in Azerbaijan. BC can be easily examined simple examination as palpation, ultrasound and mammography but in some cases, the disease is diagnosed at advanced stages, which consider as bad prognosis. However, in many cases, BC stages parameters (TNM) could not present as a prognostic factor. Recent researches show that the biology of cancer provides more information than anatomical indicators. Purpose: In this study was investigate the prognostic role of TUBB3 gene expression (exp) in the BC stage formulation as novel molecular biomarker. Patients and methods: The study involved 250 randomized patients with primary BC who were diagnosed and treated in the Chemotherapy Department II of National Center of Oncology in 2014-2016. Classic parameters which are the age of patients, tumor detection period, size of the tumor, biological subtypes, the grade of tumor and as a novel biomarker TUBB3 gene exp level were investigated formulation with the stage (s) of disease in the study. Total RNA extracted using an RNAeasy FFPE kit (Qiagen, GmbH, Germany). cDNA synthesis reaction conducted using a cDNA synthesis kit (Thermo Fisher Scientific). The beta-2-microglobulin was used as a reference gene for normalizing the exp level of the target genes. The gene exp level was calculated using the formulae 2−ΔΔСt. Results and Discussion: Patients were distributed in stages: s I-6%, s II-28%, s III-47% and s IV-20%. We tried to find a correlation between tumor stage and classic parameters such as patient age, tumor size, tumor grade, tumor biological subtypes. It has not been identified any relationships between BC stages and parameters that described upper. As a result, these BC parameters were not determined as a prognostic factor in this study. We analyzed TUBB3 gene exp in each BC s. It was indicated that the more stages of BC are getting higher, the more high exp of TUBB3 gene is appearing. In another hand, high TUBB3 gene exp level in s I is 14,31%, in s II is 23,2%, in s III is 45,8%, in s IV is 53,11% was appointed. Table 1. Conclusion: High level of TUBB3 gene exp a poor prognostic factor for breast cancer patients and also provides a piece of predictive information for treatment. We suggest that anatomic-prognostic models can be a substitute for molecular-prognostic tests.